Medical therapy for benign prostatic hyperplasia.
Lepor
H
H
Department of Urology, New York University Medical Center, New York.
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D009570:Nitriles; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D014105:Tosyl Compounds
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; D010643:Phenoxybenzamine; C041226:Terazosin; C053541:bicalutamide; D011224:Prazosin